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ABSTRACT 
     This is a pre-registered study, i.e. a study whose hypotheses and experiments designed to 
address these hypotheses have been deposited in a database before starting the experiments. 
The study aims at assessing the Gs versus Gi coupling and the potency of melatonin in the 
human version of melatonin MT1 and MT2 G-protein-coupled receptors expressed in HEK-
293T cells. The results show that these receptors are Gi but not Gs coupled. By using a standard 
procedure of modulation of 0.5 µM forskolin-induced cAMP levels, it was found that the 
potency on MT2 receptor-mediated actions is in the low nanomolar range, but the potency on 
MT1 receptor is in the high nanomolar range.  The potency of melatonin to stimulate the MT2 
receptor is similar to that of a selective agonist, N-[2-(2-methoxy-6H-isoindolo[2,1-a]indol-
11-yl)ethyl]butanamide (IIK7). Overall, the data on the potency of melatonin on its receptors 
will provide a new look for melatonin research. It is important to consider this finding for 
appropriately addressing physiological or therapeutic effects based on melatonin potency. 
Thus, the low doses of melatonin used in the existing prolonged release preparations or in other 
supplements should be revisited.   
Key words: Melatonin receptor, melatonin, sleep, cAMP, signal transduction, binding, 
pharmacokinetics.  
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1. INTRODUCTION 
 
     Aiming at finding substances to treat vitiligo, a skin disease characterized by the occurrence 
of depigmentation areas, Lerner and Case reported, in 1959, that a substance produced by the 
mammalian pineal gland, caused the aggregation of melanin near the nucleus of the amphibian 
melanocytes (1). Later, they identified the active molecule, named it (melatonin) and further 
deciphered its chemical structure: N-acetyl-5-methoxytryptamine (2). Since then many 
functions of melatonin have been discovered. At present, melatonin is very popular and is 
recommended as a supplement for a variety of uses, the most common being sleep regulation 
(3-9); it is even available via Amazon. In Europe, it is the active component of a medicine, 
CircadinR, consisting of a pharmaceutical prolonged release preparation, prescribed for sleep 
disturbances, that contains 2 mg of melatonin (10). However, no melatonin-based medicine has 
been approved by the US Food and Drug Administration (FDA), which has instead approved 
a non-selective melatonin receptor agonist, ramelteon (sold as RozeremR) (11, 12). It is 
accepted that melatonin provides benefits via its putative antioxidant action or via activation 
of specific melatonin receptors.  MT1 and MT2 receptors are the two primary melatonin 
membrane receptors, which belong to the superfamily of G-protein-coupled receptors 
(GPCRs). In both receptors, the cognate heterotrimeric protein is Gi.  The biological 
consequence of Gi activation is inhibition of adenylate cyclase, reduction of cytosolic cAMP 
levels and inhibition of protein kinase A signaling pathway (13). Interestingly, other signaling 
pathways have also been assigned to melatonin receptor activation; one of them is just the 
opposite to the canonical one, i.e. Gs coupling, activation of adenylyl cyclase and increases of 
cytoplasmic cAMP levels (14). In addition, it has also been suggested that MT1 receptors may 
couple to Gq or other G proteins, and activate protein kinase C, inositol-phosphate- and calcium 
ion-mediated signaling (15, 16).  
     Quite surprisingly, a substantial number of reports show that the potency of melatonin acting 
on its receptors is in the picomolar range, something that it is not usual for endogenous 
compounds acting on GPCRs. By using high concentrations of the adenylyl cyclase activator, 
forskolin, many studies have shown that the potency of melatonin to its receptors is in the 
subnanomolar range. Furthermore, any GPCR-mediated action, if specific, must be blocked by 
an antagonist. Very few studies contemplate the experiment of antagonist treatment to confirm 
specificity and selectivity of melatonin receptor-mediated actions. In addition, atypical outputs 
and seemingly pleiotropic signaling [see (3, 17-20) for review] led to hypothesize the existence 
of a third melatonin receptor (21), which was later identified as an enzyme rather than a 
melatonin receptor. The enzyme, human quinone reductase 2 (22), seems to be allosterically 
regulated by melatonin and other endogenous compounds (e.g. N-acetylserotonin); however, 
its role as potential mediator of melatonin physiological effects is under discussion (23-25). 
     Radioligand binding assays have led to fairly low KD values of melatonin binding to its 
receptors. Many studies were performed with iodinated-labeled melatonin-related compounds 
and it is known that iodine may unspecifically bind to membranes. To our knowledge, the 
initial study concerning 2-[125I]iodomelatonin binding to hamster brain membranes was  
reported in 1986 by Duncan et al. (26). The binding potency calculated by kinetic 
association/dissociation data, Scatchard plot analysis and competition assays led to 
monophasic curves and the estimated KD value for iodomelatonin was in the low nanomolar 
range (3.1 to 4.9 nM). In this study the reported Ki value for melatonin was 8 nM, whereas in 
a subsequent study using a similar preparation the reported value was 10.8 ± 2.1 nM (27). The 
same authors in further studies reported that the KD value of a 2-[
125I]iodomelatonin binding 
site in the hypothalamus  was 43 ± 5 pM, postulating that the hamster brain tissue shows 
nanomolar and picomolar affinities corresponded to, “ML-2” and “ML-1” sites, respectively 
(28). 
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     A more recent study reported KD values of 332 pM and 289 pM for melatonin binding to 
preparations of cells expressing MT1 and MT2 receptors, respectively (29). In Chinese hamster 
ovary CHO cells expressing either MT1 or MT2 receptors, the significant inhibitory effects of 
1 nM melatonin on 100 µM forskolin-induced cAMP cytosolic levels were observed while, 
surprisingly, the EC50 values in functional studies to assess phosphoinositide signal 
transduction cascade were in the micromolar range. Also unusual is the high concentration (1 
M) of the MT2 receptor specific antagonist, cis-4-phenyl-2-propionamidotetralin (4-P-PDOT), 
used to block MT2 receptor mediated action, while the study did not include any MT1 receptor 
specific antagonist (29). All of these data are very intriguing from a pharmacological point of 
view. 
     It has been reported that rabbit gastrointestinal smooth muscle only expresses MT1 receptor 
that couple to Gq but not to Gi. For example,  by use of [
35S] GTPgammaS labeling prior to 
immunoprecipitation of α subunits of G proteins. Ahmed et al. (30) observed  that a very high 
concentration of melatonin (1 µM) induces  an increase in the radioactivity associated to αq 
while the radioactivity associated to αi1, αi2 and αi3 (also to αs) was not significantly altered. 
Although melatonin promotes phosphoinositide turnover in a dose-dependent fashion with an 
EC50 of 4  1 nM, other functional responses (cytosolic calcium mobilization or IP hydrolysis 
in the presence of minigenes) require 1 µM concentration of melatonin (30). In summary, these 
data indicated that melatonin receptors may not couple to Gi proteins and that high 
concentrations of melatonin are required to afford receptor functionality (KD values in the 
picomolar range but EC50 values for PI hydrolysis in the low nanomolar range). Melatonin at 
the concentration of 1 µM decreases muscle contraction while the effect is reversed by a MT1 
receptor antagonist, luzindole, at a concentration of only 100 nM. If the potency of melatonin 
is in the nanomolar range (<10 nM according to dose-response curve illustrated in Fig. 5 of 
reference (30), it is difficult to believe that 100 nM luzindole will significantly inhibit the effect 
of melatonin at a concentration of 1 µM. In brief the MT1 receptor is expressed in the muscle 
cells and melatonin acts via Gq and not via Gi; however, the involvement of the receptors in the 
Gq-mediated effects is dubious as the conditions of the assays are not standard from a 
pharmacological point of view. In this regard, activation of melatonin receptors in a 
heterologous expression system does not lead to immediate Ca2+ mobilization as it occurs in 
the case of other GPCRs that are coupled to Gq (31). 
     Pre-registering is a recently developed instrument aimed at improving the reliability of 
results from experimental research. Pre-registered studies were first used for clinical trial 
implementation, but now this option is open, and convenient, for any type of scientific research. 
It consists of uploading detailed information of the hypothesis and the experimental designs in 
a database before starting the experiments. Individuals who are interested can have free access 
to such information. When, based on the experimental approaches, the results are obtained, 
they are mainly interpreted in terms of confirming or rejecting the initial hypotheses. These 
experimental approaches should match as much as possible to those that were a priori 
registered. One of the main resources is provided within the Open Science Framework (OSF), 
where pre-registered studies are deposited in https://osf.io. As it is stated by Foster and 
Deardoff (32): “Registration is a major feature of the OSF and its efforts to preserve, provide 
access to, and promote transparency in research. Any OSF project can be registered, which 
means that a time-stamped version of the project is created that cannot be edited or deleted 
and is intended to act as a preserved version of a project”. 
     As it has  been already demonstrated that melatonin receptors do not couple to Gq in the 
HEK-293T cell heterologous expression system (31), this pre-registered study (available at 
(33), by using the HEK-293T cell expression system, will evaluate  whether i) MT1 or MT2 
receptors  can couple to Gs and/or Gi proteins, ii) Gs/Gi-coupled melatonin receptors are 
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sensitive to subnanomolar concentrations of melatonin and iii) melatonin potency is similar to 
that previously reported by using other methods to measure cAMP levels.  
2. MATERIALS AND METHODS  
2.1. Chemicals. 
 
N-Acetyl-5-methoxytryptamine (melatonin), N-acetyl-2-benzyltryptamine (luzindole: non-
selective MTR antagonist), cis-4-phenyl-2-propionamidotetralin (4-P-PDOT, a selective 
MT2R antagonist) and forskolin were purchased from Tocris Bioscience (Bristol, UK). N-[2-
(2-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethyl]butanamide (IIK7, a selective MT2 receptor 
agonist) was purchased from Sigma-Aldrich (St. Louis, MO, USA).  
2.2. Cell Culture and Transient Transfection.  
     A heterologous system consisting of human HEK-293T cells was used in this study. These 
immortalized cells come from Human Embryonic Kidney (34) and are used in many 
laboratories for heterologous expression of proteins. Previous heterologous expression systems 
were not of human origin and, accordingly, the development of HEK-293T cells was a of 
paramount relevance for biomolecular research; they are currently used in biochemistry, 
pharmacology, electrophysiology and biotechnology approaches aimed at advancing 
knowledge into protein structure/function relationships (35-37). Cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 2 mM L-glutamine, 100 
U/ml penicillin/streptomycin, and 5% (v/v) heat inactivated fetal bovine serum (FBS) 
(Invitrogen, Paisley, Scotland, United Kingdom). Cells were maintained in a humid 
atmosphere of 5% CO2 at 37◦C. Cells were transiently transfected with the polyethylenimine 
(PEI, Sigma, St. Louis, MO, United States) method (38-40). Briefly, cells were incubated (4h) in a 
serum-starved medium with the corresponding cDNA and with PEI (5.47 mM in nitrogen 
residues) and 150 mM NaCl. After 4 hours, the medium was replaced by a fresh complete 
culture medium. The cDNAs used were obtained from the cDNA resource Center (Ref. 
#MTNR1A0000 for the MT1 receptor and #MTNR1B0000 for the MT2 receptor). Transfection 
efficiency (>60% of cells expressing each of the receptors) was checked using specific 
antibodies and immunocytochemical staining. 
2.3. cAMP determination.  
     Two hours before initiating the experiment, HEK-293T cell-culture medium was replaced 
by serum-starved DMEM medium. Then, cells were detached and suspended in growing 
medium containing 50 mM zardaverine. Cells were plated in 384-well microplates (2,500 
cells/well), pretreated (15 min) with the corresponding antagonists or vehicle and stimulated 
with agonists and 0.5 µM forskolin or vehicle (15 min). Readings were performed after 1 h 
incubation at 25 ºC. Homogeneous time-resolved fluorescence energy transfer (HTRF) 
measures were performed using the Lance Ultra cAMP kit (PerkinElmer, Waltham, MA, 
USA). Fluorescence at 665 nm was analyzed on a PHERAstar Flagship microplate reader 
equipped with an HTRF optical module (BMG Lab technologies, Offenburg, Germany).  
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2.3. Statistical Analysis 
     Data were analyzed using Prism 7 (GraphPad Software, Inc., San Diego, CA, United States). 
The data in graphs are the mean ± SEM. Significance was analyzed by one-way ANOVA, 
followed by Bonferroni’s multiple comparison post hoc test. Significant differences were 
considered when p < 0.05.  
3. RESULTS 
     Although Gi is the cognate heterotrimeric protein coupled to melatonin receptors, as 
classified by the International Union of Pharmacology and British Society of Pharmacology 
(13) (https://www.guidetopharmacology.org/), there have been reports on coupling to Gs, so 
we first tested whether activation of melatonin receptors increases cAMP production. Results 
in Figure 1A and 1C show that neither melatonin treatment on MT1-expressing HEK-293T 
cells or on MT2-expressing HEK-293T cells led to any significant increase in cytosolic cAMP 
levels. Therefore, in a heterologous expression system, the human versions of MT1 and MT2 
receptors are likely not Gs-coupled. In contrast, in the same experimental system, melatonin 
treatment significantly decreased the cAMP levels which previously increased upon 0.5 µM 
forskolin treatment.  
     Forskolin treatment increased cytosolic cAMP levels in both cell lines (also in untransfected 
cells) and this increase was reduced by cotreatment with melatonin at the concentration of 100 
nM in both MT1-expressing and MT2-expressing cells. In addition, it is evidenced that 
melatonin membrane receptors are coupled to Gi in a specific manner, as the cAMP-inhibitory 
effect is completely blocked by the non-selective antagonist, luzindole (N-acetyl-2-
benzyltryptamine, 1 µM), in MT1-expressing cells and by the MT2 receptor selective 
antagonist, 4-P-PDOT (0.5 µM), in MT2-expressing cells. These antagonists in the absence of 
melatonin did not significantly affect the forskolin effect on cAMP production (Figure 1B and 
D). The results confirmed that both MT1 and MT2 were specifically coupled to Gi (Figure 1B 
and D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Assessment of Gs and Gi coupling.  
     HEK-293T cells expressing MT1 receptor (A, B) or MT2 receptor (C, D) treated with vehicle 
or with either 1 or 100 nM melatonin. Gs coupling (A, C) was assessed by measuring the 
increase of cytosolic cAMP levels whereas Gi coupling (B, D) was assessed by simultaneous 
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treatment with 0.5 µM forskolin. Cytosolic cAMP levels were determined by TR-FRET as 
described in Methods. Specificity was assessed by preincubating cells with antagonists (for 15 
min): the melatonin receptor nonselective antagonist, luzindole, in MT1-expressing cells (B) 
and the MT2 receptor selective antagonist, 4-P-PDOT, in MT2-expressing cells (D). Values are 
the mean ± SEM. of 6 independent experiments performed in triplicates. One-way ANOVA 
followed by Bonferroni’s multiple comparison post hoc test were used for statistical analysis 
(*p < 0.05, ***p < 0.001 versus forskolin treatment). 
 
     To further assess receptor functionality, dose response assays were performed. At 
subnanomolar levels, no significant inhibitory effect of melatonin (MT1 expressing cells) or of 
melatonin or IIK7 (MT2 expressing cells) was detected in forskolin-induced cAMP 
determination experiments (Figure 2A and B). The calculated IC50 value of melatonin on the 
MT1 receptor was 58.0 nM (pIC50=7.24, SD 0.35) and IC50 values of melatonin and IIK7 on 
the MT2 receptor were 3.9 nM (pIC50=8.4, SD 0.22) and 7.3 nM (pIC50=8.1, SD 0.22), 
respectively (Figure 3A and B).  
 
 
Fig. 2. Effects of melatonin and IIK7 on forskolin-induced cAMP production in MT1 or 
MT2 expressing cells.  
     HEK-293T cells expressing MT1 receptor (A) or MT2 receptor (B) were treated with 0.5 µM 
forskolin and melatonin and/or IIK7 (selective MT2 agonist) at the indicated concentrations. 
In parallel, assays with cells pretreated (15 min) with antagonists: luzindole or 4-P-PDOT, 
were also performed. Cytosolic cAMP levels were determined by TR-FRET as described in 
Methods. Values are the mean ± SEM of 6 independent experiments performed in triplicates. 
No statistically significant differences were observed in any of the treatments (versus the 
forskolin treatment).  
 
     The antagonistic assays were carried out in MT2-expressing cells treated with melatonin or 
with the selective MT2 agonist IIK7 (100 nM) plus the selective MT2 antagonist, 4-P-PDOT, 
and, in MT1-expressing cells with melatonin plus luzindole. The results showed that the effect 
of 100 nM melatonin was blocked by 1 µM luzindole (Figure 3C) and both the effects of 100 
nM melatonin or 100 nM IIK7 were completely blocked by 0.5 µM 4-P-PDOT (Figure 3D). 
Taken together, the data suggest that i) the effect was specifically due to action on MT1 or MT2, 
ii) the potency of melatonin was lower on MT1 receptor than on MT2 receptor and ii) the 
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potency of the endogenous (melatonin) and the synthetic (IIK7) agonists is similar (in the low 
nM range) for MT2 receptor. 
Fig. 3. Dose-response curves and selectivity of antagonists of MT1 and of MT2.   
     Melatonin and/or IIK7 dose-response curves in HEK-293T cells expressing MT1 
receptor(A) or in cells expressing MT2 receptor (B). The conditions of the assay to measure 
effects on forskolin-induced cAMP levels were similar to those described in figure 1. Specificity 
of the effect was shown using luzindole in MT1-expressing cells (C) and 4-P-PDOT in MT2-
expressing cells (D). Panels C-D: Values are the mean ± SEM. of 6 independent experiments 
performed in triplicates. One-way ANOVA followed by Bonferroni’s multiple comparison post 
hoc test were used for statistical analysis (*p < 0.05, ***p < 0.001 versus forskolin treatment). 
 
4. DISCUSSION 
     The results here presented corroborate the hypothesis of the pre-registered study, i.e. the 
potency of melatonin does not lie in the pM but in the low nM range for MT2 and in the high 
nM range for MT1receptor. This seems different from previous concepts on the melatonin 
receptor potency. Anyway, the data will provide a new look and new vistas as to the 
melatonin’s biology and on the role of melatonin receptors in melatonin physiological 
functions (41).  
     Melatonin receptors when expressed in HEK-293T cells specifically couple to Gi and not to 
Gs (observed in the present study) or to Gq (31). This fits well with the canonical pathway 
defined by the International Union of Pharmacology and British Society of Pharmacology 
(https://www.guidetopharmacology.org/). The possibility of melatonin receptors coupling to 
Gs or Gq (even to G16) proteins reported in CHO cells, in cell lines or in intact tissues (16, 30, 
42-44) was not contemplated in this pre-registered study. However, data from our own 
laboratory have shown that Gs or Gq coupling may occur by formation of complexes involving 
melatonin receptors and other GPCRs [31]. It seems that the real potency of melatonin on the 
MT1 is lower than that previously described but such potency in terms of EC50 or IC50 values 
for proximal signaling is similar to that of other endogenous compounds acting on the 
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populated GPCR superfamily. In addition, the data related to MT2 receptor were consistent 
with the data reported  in hamster brain [26–28]. 
      There are two main inconsistencies brought about by this pre-registered study. One is 
related to MT2 receptor as our results are consistent with those of Duncan et al., who reported 
8-10.8 nM KD values for melatonin, but not with other laboratories reporting picomolar KD 
values. Another is related to MT1receptor. Almost all laboratories have claimed the potency of 
melatonin on it is in the range of pM for both KD of radioligand binding and IC50 of Gi-mediated 
effects. In a study using the same cells employed here, HEK-293 cells, forskolin-induced 
cAMP determinations in cells expressing MT1 or MT2 receptor led to IC50 values for melatonin 
being 7.7 and 117 pM, respectively (45). Thus, the differences between this report and ours do 
not seem due to the melatonin receptor expression system. However, in our study, the receptor 
specificities are investigated and this is not the case in the report by Conway et al. (45). In 
sharp contrast, the effect that we have demonstrated was, on either melatonin receptor, 
specifically blocked by selective receptor antagonists (Figure 3C and D).   
     The sequences of the plasmids used in our study are the canonical ones: GeneBank 
accession number NM005958 for MT1 and AY521019 for MT2 receptor, which are the same 
as the ones used by Conway et al. (45).  Thus, the differences between their study and ours 
may come from the concentration of forskolin, the method of cAMP level determination, which 
is now more reliable than before, and also from the approach for data acquisition and analysis.  
     Two logical questions raise from the high potency and the KD values in the pM range found 
using either MT1 or MT2 in previously published articles:  i) the specificity is (often) not 
confirmed by antagonism and ii) if the potency and KD are picomolar why melatonin is used at 
micromolar concentrations when assessing its physiological effects?  
     In summary, in this pre-registered study two important issues on melatonin research have 
been confirmed, that are, 1. both MT1 and MT2 receptors are directly coupled with Gi but not 
with Gs and Gq (may be associated with them depending on the context, as mentioned in the 
text); 2, the melatonin potency in both MT1 and MT2 receptors is significantly lower (nM) than 
that previously reported (pM). We believe that these new data, especially on the potency of 
melatonin on its receptors will provide a new perspective in melatonin research. It is important 
to consider that the amount of melatonin needed to achieve its physiological or therapeutic 
effects may be much higher than that of previously thought.  
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